Ferriprox

Ferriprox Patient Counseling Information

deferiprone

Manufacturer:

Apotex Inc

Marketer:

Quamed
Full Prescribing Info
Patient Counseling Information
Oral Solution: Instruct patients and their caregivers that FERRIPROX is light sensitive and to store FERRIPROX in the originally supplied bottle and carton. Store FERRIPROX at 20º to 25ºC (68º to 77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Instruct patients and their caregivers to store FERRIPROX out of the sight and reach of children.
Inform patients of the risks of developing agranulocytosis and instruct them to immediately interrupt therapy and report to their physician if they experience any symptoms of infection such as fever, sore throat or flu-like symptoms.
Advise patients that the amount of FERRIPROX prescribed is based on body weight and on the therapeutic goal (reduction or stabilization of the body iron load). Advise patients to use the measuring cup provided with FERRIPROX to measure the volume prescribed. Instruct patients to add about 10-15 mL of water to the measuring cup and swirl it around to mix the water with any remaining medicine in the cup and drink the mixture. The measuring cup should be hand-washed with water after use.
Advise patients to take the first dose of FERRIPROX in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking FERRIPROX with meals may reduce nausea. If a dose of this medicine has been missed, take as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not catch-up or double doses.
Advise patients to contact their physician in the event of overdose.
Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect of FERRIPROX, and it is not harmful.
Counsel women of reproductive potential to avoid pregnancy while taking FERRIPROX. Advise patients to immediately notify their physician if they become pregnant, or if they plan to become pregnant during therapy.
Inform patients that they should not breast feed while taking FERRIPROX.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in